Time controlled pulsatile transdermal delivery of nicotine: A phase I feasibility trial in male smokers
Autor: | Felix Hammann, Oliver Kummer, Georgios Imanidis, Juergen Drewe, Stefania Guercioni |
---|---|
Rok vydání: | 2016 |
Předmět: |
Adult
Male Nicotine medicine.medical_treatment Pulsatile flow Pharmaceutical Science Phases of clinical research Pharmacology Administration Cutaneous 030226 pharmacology & pharmacy Young Adult 03 medical and health sciences 0302 clinical medicine Pharmacokinetics medicine Humans Transdermal Smokers business.industry Middle Aged Clinical trial Tolerability Anesthesia Feasibility Studies Smoking cessation business 030217 neurology & neurosurgery medicine.drug |
Zdroj: | Journal of Controlled Release. 232:248-254 |
ISSN: | 0168-3659 |
DOI: | 10.1016/j.jconrel.2016.04.017 |
Popis: | Nicotine substitution is a mainstay component in smoking cessation schemes. Current products including patches are poorly effective mainly because they do not give smokers the same pharmacokinetic profile of nicotine as cigarette consumption. This work evaluates a new computer operated delivery system for time controlled pulsatile transdermal administration of nicotine in a phase I clinical trial with twelve heavy smoking male volunteers. The device was affixed to the ventral side of the leading lower arm of the subjects and was programmed to deliver two pulses of drug within 16h with three delivery rates in a consecutive dose escalation study. Tolerability of the three increasing doses of nicotine was established. Plasma concentration of nicotine exhibited two peaks and one trough and reached therapeutically effective levels that behaved linearly with the drug load concentration of the device. In vivo input rate, delivered amount and elimination kinetics were deduced by pharmacokinetic modeling to analyze device performance. Timing, dose and duration of delivery were controlled by system operation parameters. Hence, feasibility of controlled pulsatile delivery of nicotine at predetermined intervals was demonstrated. After additional optimization, preprogrammed or on demand administration to meet individualized and circadian replacement needs should improve smoking cessation efficacy. |
Databáze: | OpenAIRE |
Externí odkaz: |